Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Meibomian Gland Dysfunction Clear all
Completed Not applicable Interventional Results available

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

NCT03226769
View directory record Official record
Conditions
Meibomian Glands, Dry Eye Syndromes
Interventions
TrueTear™, Thermalon Dry Eye Compress
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

NCT04469998
View directory record Official record
Conditions
Posterior Blepharitis, Meibomian Gland Dysfunction
Interventions
AXR-270 Low Dose, AXR-270 High Dose, AXR-270 Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 22, 2026, 12:22 PM EDT
Not yet recruiting Not applicable Interventional

TearCare in Young Adults

NCT07579156
View directory record Official record
Conditions
Meibomian Gland Dysfunction (Disorder)
Interventions
TearCare®
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 29 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

TearCare System to Treat Dry Eye Disease

NCT03857919
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare, LipiFlow
Device
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Scottsdale, Arizona • Laguna Hills, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional

Evaluation of Low-Level Light Therapy on Meibomian Glands Study

NCT05859295
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
Red Low-Level Light Therapy
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

NCT03956225
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye Disease
Interventions
Systane iLux® Dry Eye System, LipiFlow® Thermal Pulsation System
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers

NCT02848222
View directory record Official record
Conditions
Contact Lens Discomfort, Dry Eye Disease, Meibomian Gland Dysfunction
Interventions
Bruder Moist Heat Compress, Washcloth
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 22, 2026, 12:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction

NCT01979887
View directory record Official record
Conditions
Meibomian Glands
Interventions
Meibum Expression
Procedure
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

NCT03888378
View directory record Official record
Conditions
Meibomian Gland Dysfunction, MGD-Meibomian Gland Dysfunction
Interventions
0.3% Topical Minocycline Ointment, 1% Topical Minocycline Ointment, Topical Vehicle Ointment
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Azusa, California • Huntington Beach, California • Inglewood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 22, 2026, 12:22 PM EDT
Recruiting Not applicable Interventional

Low Level Light Therapy & Skin Pigmentation

NCT07173530
View directory record Official record
Conditions
Dry Eye, Meibomian Gland Dysfunction (Disorder)
Interventions
Three 15-minute low-level light therapy sessions using Light Emitting Diodes of wavelength 633nm (Essilor epi-c plus).
Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 22, 2026, 12:22 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the LipiFlow System With a New Activator

NCT04500821
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Activator LFD-2100
Device
Lead sponsor
Johnson & Johnson Surgical Vision, Inc.
Industry
Eligibility
22 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Bakersfield, California • Torrance, California • Hurst, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional

Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis

NCT02952079
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye, Posterior Blepharitis
Interventions
Blephex, MiboFlo
Device
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 22, 2026, 12:22 PM EDT
Terminated Phase 4 Interventional Results available

Azithromycin for Meibomian Gland Disease

NCT03953118
View directory record Official record
Conditions
Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions
Azithromycin Oral Product, Placebo Oral
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

NCT05162261
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
Interventions
Tixel C, LipiFlow
Device
Lead sponsor
Novoxel Ltd.
Industry
Eligibility
22 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
La Jolla, California • Newport Beach, California • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 22, 2026, 12:22 PM EDT
Active, not recruiting Not applicable Interventional

Meibomian Gland Dysfunction Management

NCT03652337
View directory record Official record
Conditions
Contact Lens Discomfort, Meibomian Gland Dysfunction
Interventions
BlephEx, Manual debridement
Device
Lead sponsor
University of the Incarnate Word
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis

NCT00656539
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Dysfunction Management With ZEST Protocol

NCT03968731
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Ocular Surface Disease
Interventions
Zocular Eyelid System Treatment
Other
Lead sponsor
University of the Incarnate Word
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Contact Lens Comfort Relative to Meibomian Gland Status

NCT01819194
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
senofilcon A
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 39 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fullerton, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction

NCT00755183
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
testosterone ophthalmic solution, vehicle of testosterone ophthalmic solution
Drug
Lead sponsor
ORA, Inc.
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 22, 2026, 12:22 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 22, 2026, 12:22 PM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye

NCT01521507
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye
Interventions
LipiFlow System, Warm Compress Therapy + Lid Scrub
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
9
States / cities
Fayetteville, Arkansas • Laguna Hills, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 22, 2026, 12:22 PM EDT